Drug Profile
Lusvertikimab - OSE Immunotherapeutics/Servier
Alternative Names: Anti CD127 monoclonal antibody - OSE Immunotherapeutics; Anti IL7R - Servier; Anti interleukin-7 receptor-α monoclonal antibody - OSE Immunotherapeutics; Effi-7; IL-7 receptor antagonist - OSE Immunotherapeutics; Interleukin-7 receptor antagonist - OSE Immunotherapeutics; OSE-127; OSE-217; S-95011Latest Information Update: 01 Dec 2023
Price :
$50
*
At a glance
- Originator Effimune
- Developer OSE Immunotherapeutics; Servier; University Hospital Schleswig-Holstein
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 7 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ulcerative colitis
- Phase II Sjogren's syndrome
- Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma
- Discontinued Crohn's disease; Transplant rejection
Most Recent Events
- 01 Dec 2023 Phase-III clinical trials in Ulcerative colitis (Parenteral) before December 2023 (OSE Immunotherapeutics pipeline, December 2023)
- 06 Jul 2023 EMA’s Committee for Orphan Medicinal Products (COMP) grants a positive opinion for the designation of orphan medicine to Lusvertikimab for the treatment of Acute Lymphoblastic Leukemia (ALL)
- 06 Jul 2023 OSE Immunotherapeutics received a positive review from the Drug Safety Monitoring Board (DSMB) for a phase II trial of Lusvertikimab (OSE127) in Ulcerative colitis